NCT06959056 Evaluating the Impact of Cryo-analgesia on Recovery After Double Lung Transplantation
| NCT ID | NCT06959056 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Gasthuisberg |
| Condition | Lung Transplant; Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-01-04 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-01-04 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot trial is to learn whether the use of cryo nerve block and its effect on sensation in the chest alters recovery after bilateral lung transplantation, and to which extent these parameters are influenced. As this study is setup as a pilot study, the main questions it aims to determine the potential impacted parameters as well as their effect sizes, of cryo-analgesia on both short and long term outcomes following bilateral lung transplantation in COPD patients in a European high volume lung transplant centre. The efficacy parameters under evaluation will be: * is the highest pain score affected by the use of cryo nerve block? * Is there an effect on the lung function ? * Does cryo nerve block cause specific complications? * are patients treated with cryo nerve block still needing the same amount of morphine as a pain killer? * is the length of stay in intensive care influenced by the use of cryo nerve block? * and is the qualiy of life influenced by the use of cryo nerve block? Participants will: * undergo cryo nerve block or receive routine pain treatment after bilateral lung transplantation * be followed up during the first week after the operation, and every month to determine their pain * be asked to perform a lung function test and complete quality of life questionnaires 1, 2, 3, 6 months and 1 year after transplantation
Eligibility Criteria
Inclusion Criteria: 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. At least 18 years of age at the time of signing the Informed Consent Form (ICF) 3. Bilateral lung transplantation at UZ Leuven 4. Indication for transplantation: End stage chronic obstructive pulmonary disease (COPD) 5. Storage of lungs on classic ice, cooled system (LUNGguard® (Paragonix) or X°Port Lung Transport Device (Traferox Technologies Inc.) ) are all permitted 6. Patients that have undergone lung volume reduction or talcage are not a contraindication for participation in the study. Exclusion Criteria: 1. Unilateral lung transplantation 2. Lobar transplantation 3. Donor lung reconditioning using ex-vivo lung perfusion (EVLP) 4. Combined organ transplantation 5. Chronic opioid use pre-operatively 6. Participation in an interventional Trial with an investigational medicinal product (IMP) or device (IMD) that could potentially influence the post-operative outcomes of this study
Contact & Investigator
Hans Van Veer, MD
PRINCIPAL INVESTIGATOR
Universitaire Ziekenhuizen KU Leuven
Frequently Asked Questions
Who can join the NCT06959056 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Transplant; Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06959056 currently recruiting?
Yes, NCT06959056 is actively recruiting participants. Contact the research team at hans.vanveer@uzleuven.be for enrollment information.
Where is the NCT06959056 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT06959056 clinical trial?
NCT06959056 is sponsored by University Hospital, Gasthuisberg. The principal investigator is Hans Van Veer, MD at Universitaire Ziekenhuizen KU Leuven. The trial plans to enroll 40 participants.